The history of Self-screen is a track record in translational science. The company was founded in 2008 to advance the implementation of scientific discoveries in the field of cancer screening into routine practice. Our dedication is towards the development and clinical application of molecular assays for the early detection of cancer, thereby to the benefit of patients around the world. Currently, the company’s main focus is on cervical cancer screening and prevention. The company has two clinically validated assays on the market. We strive towards all-molecular screening to ensure objectivity, reproducibility and high-throughput possibilities. Our research and development pipeline currently focuses on the extension of our science towards other sample types, like urine, and towards other cancer types.

Part of Cosmo Pharmaceuticals NV, Cosmo Technologies Ltd. is an Irish company located in Dublin that manufactures and distributes pharmaceutical products. Salix Pharmaceuticals Ltd., now part of Bausch Health Cos., Inc. acquired Cosmo Technologies Ltd. from Cosmo Pharmaceuticals SA.\nThe company says this about itself: COSMO designs, manufactures and markets family-safe technology products. Committed to the idea that technology should be designed for families, not just repurposed from other segments, COSMO is pioneering new product categories. At the center of its offerings is its mobile application, COSMO: Mission Control. This hub for managing connected devices and family software is meant for families who are seeking a new way of doing technology.

Genfleet Therapeutics (Shanghai), Inc. is a company headquartered in Shanghai, China. The firm provides research and development services in discovering drugs. It was founded in 2017 by Qiang Lü and Jiong Lan. Jiong Lan has been the CEO since the inception date.\nThe company says this about itself: GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies, is dedicated to serving significant global unmet medical needs in oncology and immunology. Based on the deep understanding of disease biology and translational medicine, GenFleet's proprietary and fully integrated R&D platform highlights multiple cutting-edge products with novel mechanisms and global IP. Since its inception in 2017, GenFleet has built up industry-leading capabilities and expertise in developing novel drug candidates - both small molecules and biologics. Its pipeline includes over 10 programs, many of which have entered multi-regional clinical trials across China (including Taiwan), the United States, Europe and Australia. To date, GenFleet has over 5 clinical studies encompassing IND stage to phase II studies and completed co-development partnerships with a number of publicly listed companies worldwide. GenFleet is expected to progress additional programs into the clinic, as well as transition from a clinical stage biotech company into a commercial stage biopharmaceutical company in the next 3-5 years.

Ammunition is a biotech company that creates technology for early cancer detection with a focus on endometrial, colorectal, cervical, and esophageal cancer. To help clinicians effectively detect, diagnose, and treat early cancer, the firm conducts research and develops early cancer detection technologies using epigenetics, nanomaterials, bioinformatics, big data technology, and artificial intelligence analysis.

LKT Labs is a biochemical provider for life science research. The company offers services for the synthesis, purification, and isolation of small molecules for research applications. Their products include known biological activities that have found uses in research fields for cancer and neuroscience. These products include protein kinase inhibitors, ion channel modulators, and activators.

Cytyc Corporation, a diagnostic and medical device company, designs, develops, manufactures, and markets and diagnostic and surgical products. The company offers its products for a range of cancer and women's health applications, such as cervical cancer screening, menstrual bleeding treatment, early-stage breast cancer radiation treatment, and malignant brain tumors radiation treatment applications. It serves customers in the Canadian, European, and Asia/Pacific markets. The company was founded in 1987 and is based in Marlborough, Massachusetts. As of October 22, 2007, CYTYC Corporation opeartes as a subsidiary of Hologic Inc.

Exact Sciences is a molecular diagnostics company focused on colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA (sDNA) technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.

Cavion is a clinical stage pharmaceutical company committed to providing patients with therapies for cancer and neurologic diseases through the development of drugs that selectively inhibit the T-type calcium channel (Cav3). Built on the discovery by Cavion’s founders that ion channels are a target for the treatment of solid tumor cancers, they were the first company to invent therapies engaging Cav3 for the treatment of solid tumors. The innovative idea of treating pathologically proliferating, non-electrically excitable cells by targeting an ion channel has already shown success in preclinical studies and is being tested in Phase 1 safety and dose-finding clinical trials in brain cancer. Their technology is intended to magnify the effects of combined chemotherapy, radiation, and targeted therapies for all solid tumor cancers. Their neurology program uses superior chemistry and clinical expertise to deliver a novel class of drugs that will provide patients with treatments for neurologic diseases. While Cav3 is an established target in neurology, particularly neuropathic pain, Cavion is working to bring the first non-addictive, non-opioid T-type calcium channel antagonist to patients with neuropathic pain. Given that Cav3 plays a role in numerous pathologic conditions, Cavion is simultaneously developing therapies for additional neurologic afflictions such as essential tremor, Parkinson’s disease, epilepsy, and Angelman syndrome.

BioSight is a biopharmaceutical private company founded in 2000 and re launched in mid 2009, revolutionizing the research and development of innovative cancer targeted pro-drugs. BioSight has developed technology S2DOT TM and a pipeline of targeted pro-drugs, that can target and release chemotherapy drugs inside cancer cells, while significantly minimizing the systemic toxicity associated with conventional chemotherapy ​​treatments.​​​

Cancer Advances is a biotechnology company focused on impacting human health and the progression of gastrointestinal cancers by enhancing the adaptive immune system. The company is led by an experienced management team and has a broad intellectual property portfolio. Cancer Advances is a wholly owned subsidiary of Cato BioVentures. The company's lead compound, Polyclonal Antibody Stimulator (PAS), is an immunomodulator used to treat gastrointestinal cancer. Please visit their Product page for more information on what is in development.

Qurin Diagnostics BV develops diagnostic devices to non invasively detect early stage cancer of multiple types. The company was founded by Roderik Kraaijenhagen and is headquartered in Enschede, the Netherlands.

ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employs technologies, such as its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs. The Company's product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ 197 is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in Microphthalmia Transcription Factor (MiT) associated tumors, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma and hepatocellular carcinoma (HCC). The Company has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) in the United States, Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin).

Chongqing Wokang Biotechnology Co., Ltd., established on 2013-11-25, Business scope includes general items:Retailing of computer software, hardware and auxiliary equipment;Home Appliance Sales;Glassware Sales;Sales of plastic products;Mechanical Parts,Parts sales;research and development,Production,Sales:Class I,Class II,Class III medical device,Laboratory equipment and equipment,biological reagent,chemical reagent;biology,Technology development in the field of medicine,technical consulting,Technology Transfer and Technical Services..(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Manufactures vaccines for diseases like hepatitis, influenza, rubella and typhoid fever

Biochain Beijing Science & Technology, Inc. provides service of technological development for national universities and colleges, hospitals and international pharmaceutical companies. Its products include quantitative diagnostic kit for respiratory syncytical virus RNA and urea plasma urealyticum DNA. The company was founded in August 2006 and is headquartered in Beijing, China.

CM&D Pharma Ltd. provides pharmaceutical products. It is a specialty pharmacy company focused on foods for special medical purposes. Its products include Fostrap CKD, Recoclix, SilSOS, Eviendep, and Ossulin. The company was founded in 2007 and is headquartered in Surrey, UK.

Anhui Zhongke Tuoran Pharmaceutical Science Research Co., Ltd., established on 2019-07-02, Business scope includes targeted new drug research and development and technical consulting;Chemicals,Research and development of chemical raw materials;Medical Research and Experimental Development.(The above does not contain hazardous chemicals,Flammable and explosive products)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Hkg Epitherapeutics Ltd. is a private company headquartered in Hong Kong that operates research and development lab company.